LAVA Therapeutics N.V. - LVTX Income before deduction of interest, taxes and amortization

Graphic logo of LAVA Therapeutics NV (LVTX)

LAVA Therapeutics N.V. (LVTX) is developing advanced immunotherapy through partnerships with global pharmaceutical leaders. The company's operating profit on this chart confirms the current trend, with the latest mark standing at 0.00. The startup attracts leading immunologists through a flexible culture and RSUs. Organic pipeline growth is fully funded by active joint R&D programs with industry behemoths.

Profit before payment of interest, taxes and amortization: LAVA Therapeutics N.V. (LVTX) for 11/23/2025 - 12/06/2025

LAVA Therapeutics NV - analytical breakdowns and key metrics (LVTX)

- market value and analyst target forecast:
Analysis of all company metrics:LAVA Therapeutics - LVTX
Mass-produced product of LAVA Therapeutics

This indicator measures a business's net ability to generate cash flow from core operations before depreciation and taxes, allowing investors to assess operational resilience without reporting lags. By analyzing the cash volume of EBITDA, one can confirm the financial stability of LAVA Therapeutics N.V. (LVTX), whose development of immuno-oncology agents in the US and EU is protected by international medical immunity from geopolitical risks.

Competitors of LAVA Therapeutics N.V. (LVTX)

ImmunityBio (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (Janux Therapeutics, Inc.)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization tangotx.com|Operating profit before deduction of amortization iovance.com (IOVA)|Profit before payment of interest, taxes and amortization Immatics NV (IMTX)|Operating profit before deduction of amortization Xencor Corp XNCR|Compass Therapeutics Inc - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Inc. REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (innate-pharma.com) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen Ltd. (CGEN)|Operating profit before deduction of amortization IOBT|STRO - Operating profit before depreciation charges|Operating profit before deduction of amortization INKT (MiNK)|Company profit before taxes, interest and amortization HOWL|Operating profit EBITDA IMMX (Immix Biopharma, Inc.)|Income before deduction of interest, taxes and amortization ALXO|CUE - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Profit before payment of interest, taxes and amortization|MAIA Biotechnology - Income before deduction of interest, taxes and amortization|LIMN (liminatuspharma.com) - Operating profit EBITDA|Operating profit EBITDA NextCure Inc|Profit before payment of interest, taxes and amortization leaptx.com (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Biologics (TOVX) - Profit before interest, taxes and amortization|gritstonebio.com - Operating profit EBITDA|KA (Kineta) - Operating profit before amortization|NEXI: Operating profit EBITDA|Turnstone Biologics Corporation (TSBX) - Operating profit EBITDA|VCNX (vaccinex.com) - Operating profit EBITDA|HARP: Income before deduction of interest, taxes and amortization